-
Salix Pharma Reports Significant Results For Budesonide Foam In Active Mild To Moderate Ulcerative Proctitis
5/22/2013
|
|
|
-
Salix Pharmaceuticals Posts Q1 EPS Of $0.35 Vs. $0.15 Year Ago
5/9/2013
|
|
|
|
|
|
|
-
Salix Pharma Q4 EPS $0.28 Vs $0.56 Last Year
2/28/2013
|
|
|
-
RBC Capital Markets Starts Salix Pharmaceuticals Ltd (SLXP) At Outperform With $53.00 Price Target
1/11/2013
|
|
|